CareDx Inc
NASDAQ:CDNA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.57
24.91
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
CareDx Inc
CareDx Inc. is a vibrant player in the biotech landscape, navigating the intricate world of transplant medicine with a unique focus on precision diagnostics. Founded in 1998 and headquartered in South San Francisco, CareDx is deeply entrenched in the development of solutions that enhance the longevity and quality of life for organ transplant recipients. Their flagship offerings, such as AlloMap and AlloSure, are non-invasive, blood-based tests that provide critical insights into the functioning and health of transplanted organs. These tests are pivotal in assessing transplant recipients for possible organ rejection, thus presenting rapid, reliable data that may preempt irreversible damage. CareDx captures value by providing these sophisticated diagnostic tests and services to transplant centers that require cutting-edge technology to improve patient outcomes.
Revenue generation for CareDx is anchored in its comprehensive commercial approach, developing partnerships with healthcare providers and transplant centers globally. By leveraging an innovative mixture of proprietary testing technology and patient-centric solutions, the company taps into the ongoing demand for improved post-transplant care. Their business model primarily revolves around offering subscription-based services that incorporate longitudinal patient monitoring and data analytics—providing healthcare professionals with a steady flow of actionable insights. CareDx further extends its revenue streams through patient management solutions and digital health offerings, enhancing its footprint in the growing transplant diagnostics market. Beyond diagnostics, CareDx's strategic aspirations see it expanding its portfolio into more integrated healthcare solutions, resonating with healthcare practitioners seeking more personalized and predictive transplant care.
CareDx Inc. is a vibrant player in the biotech landscape, navigating the intricate world of transplant medicine with a unique focus on precision diagnostics. Founded in 1998 and headquartered in South San Francisco, CareDx is deeply entrenched in the development of solutions that enhance the longevity and quality of life for organ transplant recipients. Their flagship offerings, such as AlloMap and AlloSure, are non-invasive, blood-based tests that provide critical insights into the functioning and health of transplanted organs. These tests are pivotal in assessing transplant recipients for possible organ rejection, thus presenting rapid, reliable data that may preempt irreversible damage. CareDx captures value by providing these sophisticated diagnostic tests and services to transplant centers that require cutting-edge technology to improve patient outcomes.
Revenue generation for CareDx is anchored in its comprehensive commercial approach, developing partnerships with healthcare providers and transplant centers globally. By leveraging an innovative mixture of proprietary testing technology and patient-centric solutions, the company taps into the ongoing demand for improved post-transplant care. Their business model primarily revolves around offering subscription-based services that incorporate longitudinal patient monitoring and data analytics—providing healthcare professionals with a steady flow of actionable insights. CareDx further extends its revenue streams through patient management solutions and digital health offerings, enhancing its footprint in the growing transplant diagnostics market. Beyond diagnostics, CareDx's strategic aspirations see it expanding its portfolio into more integrated healthcare solutions, resonating with healthcare practitioners seeking more personalized and predictive transplant care.
Record Revenue: CareDx reported third quarter revenue of $100.1 million, up 21% year-over-year, driven by record results across all business segments.
Guidance Raised: The company increased full-year 2025 revenue guidance to $372–376 million and raised adjusted EBITDA guidance to $35–39 million, reflecting strong operating performance.
Cash Collection Strength: Exceptional cash collections led to $5.9 million in prior period benefit and a 38% reduction in days sales outstanding, boosting confidence in revenue predictability.
Operational Efficiency: Investments in revenue cycle management (RCM) and EPIC integration led to significant improvements in appeal volumes, claims processing, and reduced specimen holds.
Testing Volume Growth: Testing Services volume rose 13% to about 50,300 tests, with a 5% increase in revenue per test; Q4 ASP is guided at $1,400–$1,420.
Innovation Pipeline: Launched HistoMap Kidney and AlloSeq Tx11, with HistoMap expected to begin clinical use in early 2026 and commercial launch later that year.
LCD Policy Update: No business impact expected as draft Medicare policy on molecular testing is finalized, with current financial assumptions unchanged.
Market Trends: Despite flat transplant volumes nationally, CareDx outpaces the market due to low penetration and successful protocol re-adoption at centers.
